Insilico Medicine announces that its AI-designed drug candidate, rentosertib, shows promise in reversing biological aging markers. In a mid-stage clinical trial originally targeting chronic lung disease, rentosertib reduces biological age across six different aging clocks, while a placebo shows little effect. Although the findings published in Nature Biotechnology on September 7, 2026, mark a milestone for AI drug discovery, rentosertib remains years from regulatory approval and has not yet been tested on healthy patients.
Story comments
Loading comments…